All In Biotech

Drug Trial Radar · NCT00116649

Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis

Open-Label Safety and Pharmacokinetic Study of AldaraTM (Imiquimod) Cream, 5% for One, Two, or Three Treatment Cycles to Surface Areas Greater Than 25 cm2 With Actinic Keratosis

Last checked: Nov 20, 2026Latest source record: Jul 20, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

551

Actual

Start

Jun 2005

Primary completion

May 2007

Study completion May 2007

Sponsor

Lead sponsor
Graceway Pharmaceuticals, LLCIndustry
Sponsor type
Industry
First posted
Jul 1, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Actinic keratosis (AK) is a skin condition that shows up on skin routinely exposed to the sun, such as the face, scalp, shoulders, chest, back, arms, and hands. The purpose of this study is to evaluate the safety of one, two, or three cycles of imiquimod for the treatment of AK. The AK lesions treated can be in adjacent and nonadjacent areas of the head, torso, and extremities. The total surface area for the AK lesions must be greater than 25 cm2. The secondary objective is to evaluate the effectiveness of treatment with imiquimod in people with large surface areas of AK.

Conditions

  • Keratosis

Interventions

  • imiquimod creamDrug

    imiquimod 5% cream applied in doses ranging from one packet (12.5 mg) to 6 packets (75 mg) to either single or multiple body regions for up to 3 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced an Adverse EventTime frame: from first dose up to 18 months

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Encino, California

  • Site not named

    Los Angeles, California

  • Site not named

    Riverside, California

  • Site not named

    San Diego, California

  • Site not named

    Santa Monica, California

  • Site not named

    Denver, Colorado

  • Site not named

    New Britain, Connecticut

  • Site not named

    Coral Gables, Florida

  • Site not named

    Hollywood, Florida

  • Site not named

    Miami, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Arlington Heights, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Metairie, Louisiana

  • Site not named

    Boston, Massachusetts

  • Site not named

    Chaska, Minnesota

  • Site not named

    Henderson, Nevada

  • Site not named

    Henderson, Nevada

  • Site not named

    Reno, Nevada

  • Site not named

    Reno, Nevada

  • Site not named

    New York, New York

  • Site not named

    High Point, North Carolina

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Portland, Oregon

  • Site not named

    Flourtown, Pennsylvania

  • Site not named

    Arlington, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Woodbridge, Virginia

  • Site not named

    Spokane, Washington

  • Site not named

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.